Table 2 Characteristics of the study population according to colonization and infection status

Age, years, mean (± SD)

66.7 ± 13.2

66.9 ± 11.9

65.8 ± 13.9

70.7 ± 9.2

67.1 ± 15.7

67.5 ± 12.2

.597

Male/female, %

67.0/33.0

72.9/27.1

70.0/30.0

50.0/50.0

60.0/40.0

54.5/45.5

.228

ICU admission

 APACHE II

18.4 ± 6.3

18.1 ± 6.2

18.5 ± 6.1

18.2 ± 7.1

19.6 ± 7.0

18.3 ± 6.5

.925

 SOFA^a

7 (5 ; 9)

6.5 (5 ; 8)

7 (5 ; 10)

7.5 (4.5; 9.5)

6.5 (4 ; 10)

7.5 (5 ; 9)

.583

Maximum score during ICU stay

 APACHE II

18.7 ± 6.3

17.7 ± 6.6

18.3 ± 6.1

21.4 ± 7.7

19.4 ± 5.0

19.5 ± 4.7

.162

 SOFA^a

7 (5–10)

7 (4–9)

7 (5–10)

7 (5–10)

7 (5–12)

9 (5.5–10)

.702

  Candida score^a

4 (3–4)

3 (2–4)

4 (3–4)

4 (3–5)

4.5 (4–5)

3 (3–4)

< .001

ICU length of stay, days^a

15 (10–25)

12 (8–19)

14 (9–25)

21 (17–28)

14 (11–19)

16 (8–38)

.017

Hospital length of stay, days^a

37 (21–57)

34 (22–45)

33 (19–59)

48 (33–68)

37 (26–58)

40 (32–59)

.097

Patient type, no. (%)

.180

 Medical

22 (9.4)

5 (10.4)

12 (9.2)

2 (8.3)

0

3 (27.3)

 Surgical^*

211 (90.6)

43 (89.6)

118 (90.8)

22 (91.7)

20 (100)

8 (72.7)

Pancreatitis not intervened

22 (9.4)

5 (10.4)

12 (9.2)

2 (8.3)

0

3 (27.3)

.232

Site of abdominal surgery, no. (%)

.701

Esophagus

13 (6.2)

4 (9.3)

5 (4.2)

2 (9.1)

2 (10.0)

0

Stomach/duodenum

21 (10.0)

1 (2.3)

14 (11.9)

3 (13.6)

3 (15.0)

0

Biliary tract/pancreas

58 (27.5)

9 (20.9)

38 (32.2)

5 (22.7)

3 (15.0)

3 (37.5)

Small intestine

45 (21.3)

13 (30.2)

21 (17.8)

4 (18.2)

5 (25.0)

2 (25.0)

Colon

59 (28.0)

12 (27.9)

32 (27.1)

6 (27.3)

6 (30.0)

3 (37.5)

Others

15 (7.1)

4 (9.3)

8 (6.8)

2 (9.1)

1 (5.0)

0

Surgery type^**, no. (%)^†

.556

 Emergency

135 (64.0)

24 (55.8)

78 (66.1)

13 (59.1)

15 (75.0)

5 (62.2)

 Elective

76 (36.0)

19 (44.2)

40 (33.9)

9 (40.9)

5 (25.0)

3 (37.5)

Surgical procedure^**, no. (%)

.023

 One

113 (53.6)

23 (53.5)

70 (59.3)

11 (50.0)

4 (20.0)

5 (62.5)

  ≥ Two

98 (46.4)

20 (46.5)

48 (40.7)

11 (50.0)

16 (80.0)

3 (37.5)

Underlying illnesses, no. (%)

 Solid tumor

84 (36.1)

19 (39.6)

43 (33.1)

10 (41.7)

8 (40.0)

4 (36.4)

.853

 Diabetes mellitus

67 (28.8)

13 (27.1)

35 (26.9)

8 (33.3)

7 (35.0)

4 (36.4)

.830

 COPD

37 (15.9)

13 (27.1)

17 (13.1)

3 (12.5)

4 (20.0)

0

.112

 Chronic renal failure

26 (11.2)

3 (6.2)

14 (10.8)

5 (20.8)

2 (10.0)

2 (18.2)

.337

 Heart failure

16 (6.9)

3 (6.2)

6 (4.6)

5 (20.8)

0

2 (18.2)

.023

 Chronic liver failure

9 (3.9)

4 (8.3)

3 (2.3)

2 (8.3)

0

0

.201

 Oncohematologic process

3 (1.3)

0

2 (1.5)

1 (4.2)

0

0

.635

Antifungal treatment, no. (%)

119 (51.1)

21 (43.8)

58 (44.6)

11 (45.8)

18 (90.0)

11 (100)

< .001

ICU mortality, no. (%)

50 (21.5)

8 (16.7)

30 (23.1)

7 (29.7)

4 (20.0)

1 (9.1)

.605

Overall mortality, no. (%)

68 (29.2)

10 (20.8)

41 (31.5)

8 (33.3)

8 (40.0)

1 (9.1)

.277